
Uppsala Reports editor
@UMCGlobalSafety
Research / 07 October 2024
The READUS-PV statement is the first-ever guide for reports of disproportionality analyses that are replicable, reliable, and reproducible.
Disproportionality analyses are a mainstay of pharmacovigilance research, but despite their prevalence are often misinterpreted, misunderstood, and sometimes misguided.
This is why Michele Fusaroli, Daniele Sartori, and their colleagues published the READUS-PV statement, the first-ever guide to reporting disproportionality analyses. Tune in to find out more about these guidelines and how they came to be, the history and overall impact of guidelines in pharmacological research, and what it means to publish "good" pharmacovigilance science.
Subscribe by visiting the Drug Safety Matters website.
To tackle the lack of medicine and vaccine safety data for pregnant people, UMC has developed an algorithm to more easily identify pregnancy-related reports in VigiBase.
Research / 21 January 2025
AI holds potential to transform pharmacovigilance. But navigating the risks requires critical assessment. This article explores AI's evolving role in medicines safety.
Research / 22 October 2024
Medication errors are a key pharmacovigilance issue, especially as patients transition between secondary and primary care as they readjust to life outside of hospital.
Research / 09 September 2024